FY2025 EPS Estimates for Genmab A/S Raised by HC Wainwright

Genmab A/S (NASDAQ:GMAB - Free Report) - Equities research analysts at HC Wainwright lifted their FY2025 earnings per share estimates for Genmab A/S in a research report issued on Thursday, April 24th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of $1.58 for the year, up from their prior estimate of $1.48. HC Wainwright currently has a "Buy" rating and a $37.00 price target on the stock. The consensus estimate for Genmab A/S's current full-year earnings is $1.45 per share. HC Wainwright also issued estimates for Genmab A/S's Q4 2025 earnings at $0.47 EPS, Q1 2026 earnings at $0.29 EPS, Q2 2026 earnings at $0.53 EPS, Q3 2026 earnings at $0.51 EPS and Q4 2026 earnings at $0.52 EPS.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%.

A number of other analysts also recently issued reports on the company. Sanford C. Bernstein downgraded Genmab A/S from a "market perform" rating to an "underperform" rating in a research report on Tuesday, April 1st. Leerink Partners raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective on the stock in a report on Thursday, February 13th. BNP Paribas raised shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 11th. William Blair raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a report on Tuesday, March 11th. Finally, Truist Financial reduced their price objective on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a research note on Tuesday, March 11th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $39.17.

Genmab A/S Trading Up 3.3 %

Shares of NASDAQ:GMAB traded up $0.69 during mid-day trading on Monday, reaching $21.62. The company had a trading volume of 406,659 shares, compared to its average volume of 1,054,527. Genmab A/S has a one year low of $17.24 and a one year high of $30.41. The company's 50-day moving average price is $20.36 and its 200-day moving average price is $20.98. The firm has a market cap of $13.87 billion, a price-to-earnings ratio of 12.42, a PEG ratio of 2.65 and a beta of 1.07.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of GMAB. GAMMA Investing LLC increased its holdings in shares of Genmab A/S by 96.6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock worth $45,000 after buying an additional 1,051 shares during the last quarter. Crossmark Global Holdings Inc. increased its stake in Genmab A/S by 8.8% in the fourth quarter. Crossmark Global Holdings Inc. now owns 41,622 shares of the company's stock valued at $868,000 after acquiring an additional 3,377 shares during the last quarter. SG Americas Securities LLC increased its stake in Genmab A/S by 82.7% in the fourth quarter. SG Americas Securities LLC now owns 26,396 shares of the company's stock valued at $551,000 after acquiring an additional 11,949 shares during the last quarter. Blue Trust Inc. raised its position in Genmab A/S by 33.4% during the fourth quarter. Blue Trust Inc. now owns 5,757 shares of the company's stock valued at $120,000 after purchasing an additional 1,442 shares in the last quarter. Finally, R Squared Ltd bought a new stake in Genmab A/S during the fourth quarter worth about $93,000. Hedge funds and other institutional investors own 7.07% of the company's stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.